摘要
为探讨乳腺癌Ｐ６２ｃ－ｍｙｃ蛋白在乳腺癌中的表达及其临床意义，采用ＬＳＡＢ免疫组化法对１０７例乳腺癌标本进行Ｐ６２ｃ－ｍｙｃ蛋白的检测。结果显示：Ｐ６２ｃ－ｍｙｃ蛋白表达阳性率为６３．５５％（６８／１０７），对生存时间≤５年、＞５年～＜１０年和≥１０年者，其Ｐ６２ｃ－ｍｙｃ蛋白表达阳性率分别为９４．００％（４７／５０），６５．００％（１３／２０）和２１．６２％（８／３７）；Ｐ６２ｃ－ｍｙｃ蛋白过度表达与乳腺癌的临床分期，组织学分级，腋淋巴结转移有关，由此提示Ｐ６２ｃ－ｍｙｃ蛋白表达是判断乳腺癌预后的一个重要指标。
The objective of this study was to determine the clinical significance of P62 c myc protein expression in breast cancer. P62 c myc protein was detected in 107 patients with breast cancer by immunohistochemical techniques (LSAB). The results showed that the positive rate of P62 c myc protein expression was 63 55% (68/107). The over expression of P62 c myc protein related negatively with survival. 94.00% of the cases with overexpression of P62 c myc protein survived ≤5 years, 65.00% survived >5 years-<10 yeras, and 21.62% survived ≥10 years. There were significant associations of P62 c myc expression with advance clinical stage, high histological grade, and positive axillary node status in breast cancers. All of these findings suggested that overexpression of P62 c myc might be an important prognostic factor, and the detection of P62 c myc protein might be arranged as a regular pathological examination in the cases of breast cancer.
出处
《华西医科大学学报》
CSCD
1998年第4期399-401,共3页
Journal of West China University of Medical Sciences
基金
卫生部科研基金
